



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 11 Apr 2023 (#14)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

## Important Notices

**[NOT-DC-23-007](#) Notice of NIDCD Participation in [PAR-21-251](#) "Emerging Global Leader Award (K43 Independent Clinical Trial Required)" and [PAR-21-252](#) "Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)"** For the purpose of this initiative, NIDCD is especially interested in applications focused on the following topics within the NIDCD mission: otitis media, hearing loss, early hearing detection and intervention including newborn screening programs, chemosensory loss, health services, habilitation and rehabilitation services, dissemination and implementation research, and cultural and linguistic adaptations of diagnostic and intervention tools for communication disorders. Applications from institutions within a geographic region that share the same spoken language (e.g., Spanish in Latin America, Arabic in the Middle East and North Africa, etc.) could offer special opportunities for regional collaboration. Prospective applicants are encouraged to review the current [NIDCD Strategic Plan](#) on the [NIDCD website](#).

**[NOT-HG-23-028](#) Notice of Intent to Publish a Funding Opportunity Announcement for Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed)**. The National Human Genome Research Institute intends to renew the NHGRI Human Genome Reference Program (HGRP) to continue to improve the human pangenome reference resource. During the renewal phase there will be a new emphasis on community outreach and adoption of the resource and ensuring that it is useful to the full range of investigators working with or relying on human genetic and genomic data. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. **Expected Number of Awards:** 3 in FY2024; 3 in FY2025. Non-domestic (non-U.S.) Entity (Foreign Organization) expected to be eligible.

## Parent Announcements

**[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities**. Current Key Dates  
*Expiration Date: May 8, 2023 Modified Key Dates Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

**[NOT-CA-23-052](#) Administrative Supplements to Study the Economics of Cancer Control in Low- and Middle-Income Countries (LMICs).** The purpose of this Notice is to encourage currently funded NCI extramural investigators to apply for administrative supplements to study cancer control and prevention in low- and middle-income country (LMIC) settings using economic or costing data and methods. Research may involve the use of economic data to assess medical costs associated with cancer control or care, to understand non-medical costs, or to study the application of economic data to inform policy decisions. Studies may utilize a range of possible approaches including original data collection, secondary data analysis, modeling using available data, or methods development. The parent award need not have included an economic outcome or measures. However, the supplemental funding request must propose to enhance the parent award through incorporating economic or costing analyses or methods to extend the existing research aims. Applicants are encouraged to leverage existing resources and partnerships, and to design projects that can reasonably be completed within the given time and budget. **Administrative supplement applications are limited to currently funded R01, R21, R33, R37, P01, P20, P30, P50, U19, U01, UH3, or U54 projects** supported by NCI. Requests for no-cost extensions on the parent grant to accommodate a supplement will not be permitted. Administrative supplement applications are limited to currently funded R01, R21, R33, R37, P01, P20, P30, P50, U19, U01, UH3, or U54 projects supported by NCI. Requests for no-cost extensions on the parent grant to accommodate a supplement will not be permitted. *Applications can be submitted on a rolling basis between April 4, 2023 - May 30, 2023, at 5:00 PM local time of applicant organization for FY 2023 funding. The NOSI will expire May 31, 2023.* Budget requests cannot exceed \$150,000 in total costs and must reflect the actual needs of the proposed budget. The application budget is limited to 1 year only.

**[NOT-DA-24-006](#) Leveraging glial cells to treat addiction.** This Notice of Special Interest (NOSI) encourages studies to exploit the unique properties and functions of glial cells and develop strategies to mitigate Central Nervous System (CNS) damage due to acute or chronic exposure to addictive substances or therapeutic avenues for addiction treatments. This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through September 8, 2026.

**[NOT-DC-23-009](#) Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism.** The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language and communication in autistic individuals who are minimally verbal/non-speaking. Further research is needed to evaluate and tailor existing interventions, develop novel interventions, develop and apply new research designs and methods to intervention efforts, and identify meaningful outcome measures. This notice applies to due dates on or after June 5, 2023, and subsequent receipt dates through June 6, 2026.

**[NOT-EY-23-005](#) Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research.** The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research. This notice applies to due dates on or after June 16, 2023, and subsequent receipt dates through February 16, 2026.

## Notice Funding Opportunity (NOFO)

### 1. Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-141](#)

**Type:** R01

**Application Due Date:** May 01, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The Vision Research Collaborative (VRC) is a joint initiative between the National Eye Institute (NEI) and the Congressionally Directed Medical Research Programs (CDMRP) Vision Research Program (VRP) of the Department of Defense (DOD). The goal of this partnership is to provide additional funding opportunities for VRP proposals, enhance current NEI Program portfolios, expand the scope of research supported by the NEI, and provide support for high quality projects addressing critical gaps in civilian and military vision research. Only PI's who have received an invitation from the NEI to submit a reformatted application to the NIH will be considered.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

### 2. Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-164](#)

**Type:** R01

**Application Due Date:** June 05, 2023 through to May 07, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion NOFO ([PAR-23-164](#)).

**Budget:** Application budgets are not limited but, need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application.

### 3. Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-165](#)

**Type:** R01

**Application Due Date:** June 05, 2023 through to May 07, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to NOFO ([PAR-23-164](#)).

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Scope of the proposed project should determine the project period. The maximum period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application.

### 4. Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated Disease (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-23-028](#)

**Type:** R01

**Application Due Date:** August 25, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to promote basic research to better understand the mechanisms underlying viral invasion of the central nervous system (CNS), virus- and/or host immune-mediated neuropathogenesis, and the associated clinical manifestations for emerging and re-emerging neurotropic viruses.

**Budget:** NIAID intends to commit \$2.8 million in FY 2024 to fund 5-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 5. Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-23-033](#)

**Type:** U01

**Application Due Date:** December 15, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to support Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure. Specifically, this NOFO solicits applications that will identify, understand, and develop strategies to address barriers to the adoption, integration, and sustainability of evidence-

based cancer control interventions among PLWH in LMICs and generate data in LMICs that can inform effective and equitable implementation of evidence-based cancer control for PLWH worldwide. Responsive applications should include multi-disciplinary teams of researchers with expertise in HIV, cancer, and implementation science to address the cancer control needs of PLWH populations specific to the proposed LMIC context.

**Budget:** NCI intends to commit \$5.0 million in FY 2024 to support up to 6 awards. Application budgets are limited to \$500,000 in direct costs per year. The maximum project period is 5 years.

#### 6. Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DE-24-001](#)

**Type:** R01

**Application Due Date:** July 24, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).

**Budget:** NIDCR intends to commit \$ 2.5 million in FY 2024 to support 3-5 awards solicited through [RFA-DE-24-001](#) and [RFA-DE-24-002](#), contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NCI intends to commit \$ 1.8 million in FY 2024 to support 2-3 awards solicited through [RFA-DE-24-001](#), contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

#### 7. Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R21 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DE-24-002](#)

**Type:** R21

**Application Due Date:** July 24, 2023 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to solicit developmental/exploratory research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).

**Budget:** Application budgets are limited to \$275,000 in direct costs over the two-year period, with a maximum of \$200,000 in direct costs allowed in any single year. The maximum project period is 2 years.

#### 8. Developing Measures to Advance Quality in Mental Health Care Services (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-23-265](#)

**Type:** R01

**Application Due Date:** October 10, 2023 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The aim of this Notice of Funding Opportunity (NOFO) is to support the development, testing, and validation of outcome-focused mental health care quality measures, in a form suitable for submission to, and endorsement by, relevant regulatory or governing bodies. Outcome-focused quality measures take the form of assessing the fraction of a given group of patients – e.g., those served by a given clinician, facility, health system, or health plan – whose outcomes meet or exceed certain specified clinical objectives. While standardized instruments for assessing patient clinical status are plentiful, there is a gap in the translation of standardized instruments of patients' clinical status into outcome-focused measures of mental health care. Endorsement by relevant regulatory or governing bodies will facilitate implementation of these measures, for example, into clinical practice, health care quality reporting, and alternative payment programs.

**Budget:** NIMH intends to commit \$1,500,000 in FY 24 to fund up to 4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

Research Development and Support Division (RDSD) &  
Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105